Maze Therapeutics (MAZE) Return on Capital Employed (2025 - 2026)
Maze Therapeutics' (MAZE) quarterly Return on Capital Employed came in at 34.62% in Q1 2026, down 3605.0% year-on-year from 0.99% in Q1 2025, and up 6.23% quarter-over-quarter from 36.92% in Q4 2025.
Maze Therapeutics (MAZE) Return on Capital Employed (2025 - 2026) Analysis & Trends
Maze Therapeutics has disclosed Return on Capital Employed across 2 years of filings, most recently posting 34.62% for Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 34.62%, down 3605.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 34.62% (down 3605.0% YoY), and the FY2025 annual result was 48.23%, changed N/A from the prior year.
- Return on Capital Employed came in at 34.62% for Q1 2026 at Maze Therapeutics, up from 36.92% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 1.43% in Q1 2025 to a low of 57.73% in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | 450.31% |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 51.73% |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -107.40% |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 21.10% |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | -50.43% |
| 10 | Maze Therapeutics | 1.31 Bn | 1.31 Bn | 18.21 Mn | -34.62% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -34.62% |
| Dec 31, 2025 | -36.92% |
| Sep 30, 2025 | -53.11% |
| Jun 30, 2025 | -57.73% |
| Mar 31, 2025 | 1.43% |